NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA on Thursday issued a final local coverage determination for Castle Biosciences' DecisionDx-Melanoma assay, a prognostic test for cutaneous melanoma that helps guide use of sentinel lymph node biopsy (SLNB).
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.